Pharmacogenetics of Drugs Withdrawn from the Market

• WHO. Promoting Rational Use of Medicines: Core Components. WHO Policy Perspectives on Medicines 5. WHO, Geneva, Switzerland (2002).
   Google Scholar
• Man F , ThorntonA, MybeckK et al. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets-1960 to 1999. Drug Inf. J. 35 , 293–317 (2001).
   Google Scholar
• Splawski I , ShenJ, TimothyKW et al. Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1 and KCNE2. Circulation 102(10) , 1178–1185 (2000).
   PubMed Web of Science ®Google Scholar
• James WP , CatersonID, CoutinhoW et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N. Engl. J. Med. 363(10) , 905–917 (2010).
   PubMed Web of Science ®Google Scholar
• Bae SK , CaoS, SeoKA et al. Cytochrome P450 2B6 catalyzes the formation of pharmacologically active sibutramine (N-{1-[1-(4-chlorophenyl) cyclobutyl]-3-methylbutyl}-N, N-dimethylamine) metabolites in human liver microsomes. Drug Metab. Dispos. 36(8) , 1679–1688 (2008).
   PubMed Web of Science ®Google Scholar
• Chung JY , JangSB, LeeYJ, ParkMS, ParkK. Effect of CYP2B6 genotype on the pharmacokinetics of sibutramine and active metabolites in healthy subjects. J. Clin. Pharmacol.51(1) , 53–59 (2011).
   PubMed Web of Science ®Google Scholar
• Kim KA , SongWK, ParkJY. Association of CYP2B6, CYP3A5 and CYP2C19 genetic polymorphisms with sibutramine pharmacokinetics in healthy Korean subjects. Clin. Pharmacol. Ther.86 , 51–58 (2009).
   Google Scholar
• Kim KS , KimEJ, LeeHA et al. Effect of sibutramine HCl on cardiac hERG K+ channel. Mol. Cell. Biochem. 320 , 125–131 (2009).
   PubMed Web of Science ®Google Scholar
• Harrison WM , ClarkDW, HillGR, ReesMI, SkinnerJR. QT interval prolongation associated with sibutramine treatment. Br. J. Clin. Pharmacol.61(4) , 464–469 (2006).
   PubMed Web of Science ®Google Scholar
• Hsiao DJ , WuLS, HuangSY, LinE. Weight loss and body fat reduction under sibutramine therapy in obesity with the C825T polymorphism in the GNB3 gene. Pharmacogenet. Genomics19(9) , 730–733 (2009).
   PubMed Web of Science ®Google Scholar
• Olden K , De Garmo RG, Jhingran P et al. Patient satisfaction with alosetron for the treatment of women with diarrhea predominant irritable bowel syndrome. Am. J. Gastroenterol.97(12) , 3139–3146 (2002).
   PubMed Web of Science ®Google Scholar
• Zhu Z , SunZS. Alosetron withdrawn from the market only 9 months after marketing. J. Chinese Pharm.36(3) , 211 (2001).
   Google Scholar
• Chang L , CheyWD, HarrisL, OldenK, SurawiczC, SchoenfeldP. Incidence of ischemic colitis and serious complications of constipation among patients using alosteron systematic review of clinical trials and post-marketing surveillance data. Am. J. Gastroenterol.101(5) , 1069–1079 (2006).
   PubMed Web of Science ®Google Scholar
• Camilleri M , AtanasovaE, CarlsonPJ et al. Serotonin transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 123(2) , 425–432 (2002).
   PubMed Web of Science ®Google Scholar
• Atkinson W , LockhartS, WhorwellPJ, KeevilB, HoughtonLA. Altered 5-hyroxytryptamine signaling in patients with constipation-and diarrhea-predominant irritable bowel syndrome. Gastroenterology130(1) , 34–43 (2006).
   PubMed Web of Science ®Google Scholar
• Camilleri M , BusciglioI, CarlsonP et al. Candidate genes and sensory functions in health and irritable bowel syndrome. Am. J. Physiol. Gastrointest. Liver Physiol. 295(2) , G219–G225 (2008).
   PubMed Web of Science ®Google Scholar
• Yap YG , CammAJ. Potential cardiac toxicity of H1-antihistamines. Clin. Allergy Immunol.17 , 389–419 (2002).
   PubMedGoogle Scholar
• Silvestre JS , ProusJR. Comparative evaluation of hERG potassium channel blockade by antipsychotics. Methods Find. Exp. Clin. Pharmacol.29(7) , 457–465 (2007).
   PubMedGoogle Scholar
• Zhou Z , VorperianVR, GongQ, ZhangS, JanuaryCT. Block of HERG potassium channels by the anfihistamine astemizole and its metabolites desmethylastemizole and norastemizole. Cardiovasc. Electrophysiol.10(6) , 836–843 (1999).
   PubMed Web of Science ®Google Scholar
• Matsumoto S , HiramaT, MatsubaraT, NagataK, YamazoeY. Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole. Drug Metab. Dispos.30(11) , 1240–1245 (2002).
   PubMed Web of Science ®Google Scholar
• Matsumoto S , HiramaT, KimHJ, NagataK, YamazoeY. In vitro inhibition of human small intestinal and liver microsomal astemizole O-demethylation different contribution of CYP2J2 in the small intestine and liver. Xenobiotica33(6) , 615–623 (2003).
   PubMed Web of Science ®Google Scholar
• Lee SS , JeongHE, LiuKH et al. Identification and functional characterization of novel CYP2J2 variants G312R variant causes loss of enzyme catalytic activity. Pharmacogenet. Genomics 15(2) , 105–113 (2005).
   PubMed Web of Science ®Google Scholar
• Yamazaki H , OkayamaA, ImaiN, GuengerichFP, ShimizuM. Inter-individual variation of cytochrome P4502J2 expression and catalytic activities in liver microsomes from Japanese and Caucasian populations. Xenobiotica36(12) , 1201–1209 (2006).
   PubMed Web of Science ®Google Scholar
• Yamamoto K , TamuraT, ImaiR, YamamotoM. Acute canine model for drug-induced torsades de pointes in drug safety evaluation-influences of anesthesia and validation with quinidine and astemizole. Toxicol. Sci.60(1) , 165–176 (2001).
   PubMed Web of Science ®Google Scholar
• Ficker E , Obejero-PazCA, ZhaoS, BrownAM. The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations. J. Biol. Chem.277(7) , 4989–4998 (2002).
   PubMed Web of Science ®Google Scholar
• Judson R . Pharmacogenomics in drug development and clinical research. In: Electrical Diseases of the Heart. Springer-Verlag, NY, USA, 677–690 (2008).
   Google Scholar
• Mück W . Clinical pharmacokinetics of cerivastatin. Clin. Pharmacokinet.39(2) , 99–116 (2000).
   PubMed Web of Science ®Google Scholar
• Staffa JA , ChangJ, GreenL. Cerivastatin and reports of fatal rhabdomyolysis. N. Engl. J. Med.346(7) , 539–540 (2002).
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ , NiemiM, BackmanJT. Drug interactions with lipid-lowering drugs mechanisms and clinical relevance. Clin. Pharmacol. Ther.80(6) , 565–581 (2006).
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T , TangC, QiuY, MuL, SubramanianR, LinJH. Effects of fibrates on metabolism of statins in human hepatocytes regulatory region. Drug Metab. Dispos.30(11) , 1280–1287 (2002).
   PubMed Web of Science ®Google Scholar
• Kameyama Y , YamashitaK, KobayashiK, HosokawaM, ChibaK. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15 + C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet. Genomics15(7) , 513–522 (2005).
   PubMed Web of Science ®Google Scholar
• Vladutiu GD , IsacksonPJ. SLCO1B1 ariants and statin-induced myopathy. N. Engl. J. Med.360(3) , 304 (2009).
   PubMedGoogle Scholar
• Ishikawa C , OzakiH, NakajimaT et al. A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin. J. Hum. Genet. 49(10) , 582–585 (2004).
   PubMed Web of Science ®Google Scholar
• Maclennan S , AugoodC, Cash-GibsonL, LoganS, GilbertRE. Cisapride treatment for gastro-oesophageal reflux in children. Cochrane Database Syst. Rev.14(4) , CD002300 (2010).
   Google Scholar
• Michalets EL , WilliamsCR. Drug interactions with cisapride clinical implications. Clin. Pharmacokinet.39(1) , 49–75 (2009).
   Google Scholar
• Wang SH , LinCY, HuangTY, WuWS, ChenCC, TsaiSH. QT interval effects of cisapride in the clinical setting. Int. J. Cardiol.80(2–3) , 179–183 (2001).
   PubMed Web of Science ®Google Scholar
• Cools F , BenatarA, BougatefA, VandenplasY. The effect of cisapride on the corrected QT interval and QT dispersion in premature infants. J. Pediatr. Gastroenterol. Nutr.33 , 178–181 (2001).
   PubMed Web of Science ®Google Scholar
• Lowry JA , KearnsGL, Abdel-RahmanSM et al. Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo. Clin. Pharmacol. Ther. 73(3) , 209–222 (2003).
   PubMed Web of Science ®Google Scholar
• Yang P , KankiH, DroletB et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 105 , 1943–1948 (2002).
   PubMed Web of Science ®Google Scholar
• Napolitano C , SchwartzPJ, BrownAM et al. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J. Cardiovasc. Electrophysiol. 11(6) , 691–696 (2000).
   PubMed Web of Science ®Google Scholar
• Finley MR , LiY, HuaF et al. Expression and coassociation of ERG1, KCNQ1, and KCNE1 potassium channel proteins in horse heart. Am. J. Physiol. Heart Circ. Physiol. 283(1) , H126–H138 (2002).
   PubMed Web of Science ®Google Scholar
• Lees-Miller JP , DuanY, TengGQ, DuffHJ. Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes involvement of S6 sites. Mol. Pharmacol.57 , 367–374 (2000).
   PubMed Web of Science ®Google Scholar
• Makita N , HorieM, NakamuraT et al. Drug-induced long-QT syndrome associated with a subclinical SCN5A mutation. Circulation 106 , 1269–1274 (2002).
   PubMed Web of Science ®Google Scholar
• Liu K , YangT, ViswanathanPC, RodenDM. New mechanism contributing to drug-induced arrhythmia rescue of a misprocessed LQT3 mutant. Circulation112(21) , 3239–3246 (2005).
   PubMed Web of Science ®Google Scholar
• Elangbam CS . Current strategies in the development of anti-obesity drugs and their safety concerns. Vet. Pathol.46 , 10–24 (2009).
   PubMed Web of Science ®Google Scholar
• Abenhaim L , MorideY, BrenotF et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N. Engl. J. Med. 335 , 609–616 (1996).
   PubMed Web of Science ®Google Scholar
• Yang J . Withdrawal of fenfluramine and dexfenfluramine from the market and related adverse drug reactions. J. Adverse Drug Reactions1(1) , 14–17 (1999).
   Google Scholar
• Humbert M , DengZ, SimonneauG et al. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur. Respir. J.20(3) , 518–523 (2002).
   PubMed Web of Science ®Google Scholar
• Morse JH . Bone morphogenetic protein receptor 2 mutations in pulmonary hypertension. Chest121(3) , 50S–53S (2002).
   PubMed Web of Science ®Google Scholar
• Blanpain C , Le Poul E, Parma J et al. Serotonin 5-HT(2B) receptor loss of function mutation in a patient with fenfluramine associated primary pulmonary hypertension. Cardiovasc. Res.60(3) , 518–528 (2003).
   PubMed Web of Science ®Google Scholar
• Gross AS , PhillipsAC, RieutordA, ShenfieldGM. The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine. Br. J. Clin. Pharmacol.41(4) , 311–317 (1996).
   PubMed Web of Science ®Google Scholar
• Patnaude LA , UndemBJ, O‘RourkeST. Dexfenfluramine-induced contraction of human and rat isolated pulmonary arteries. Eur. J. Pharmacol.401(2) , 229–234 (2000).
   PubMed Web of Science ®Google Scholar
• Jüni P , NarteyL, ReichenbachS, SterchiR, DieppePA, EggerM. Risk of cardiovascular events and rofecoxib cumulative meta-analysis. Lancet364(9450) , 2021–2029 (2004).
   PubMed Web of Science ®Google Scholar
• Zhang JY , ZhanJ, CookCS, IngsRM, BreauAP. Involvement of human UGT2B7 and 2B15 in rofecoxib metabolism. Drug Metab. Dispos.31(5) , 652–658 (2003).
   PubMed Web of Science ®Google Scholar
• Davies NM , TengXW, SkjodtNM. Pharmacokinetics of rofecoxib a specific cyclo-oxygenase-2 inhibitor. Clin. Pharmacokinet.42(6) , 545–556 (2003).
   PubMed Web of Science ®Google Scholar
• Germaine CG , BogatyP, BoyerL, HanleyJ, EngertJC, BrophyJM. Genetic polymorphisms and the cardiovascular risk of non-steroidal anti-inflammatory drugs. Am. J. Cardiol.105(12) , 1740–1745 (2010).
   PubMed Web of Science ®Google Scholar
• Arehart E , StithamJ, AsselbergsFW et al. Acceleration of cardiovascular disease by a dysfunctional rostacyclin receptor mutation potential implications for cyclooxygenase-2 inhibition. Circ. Res. 102(8) , 986–993 (2008).
   PubMed Web of Science ®Google Scholar
• Sertindole new drug. Another ‘atypical‘ neuroleptic; QT prolongation. Prescrire Int.16(88) , 59–62 (2007).
   PubMedGoogle Scholar
• Lançon C , ToumiM, SapinC, HansenK. The sertindole safety survey: a retrospective analysis under a named patient use programme in Europe. BMC Psychiatry18(8) , 57 (2008).
   Google Scholar
• Nielsen J , AndersenMP, GraffC et al. The effect of sertindole on QTD and TPTE. Acta Psychiatr. Scand. 121(5) , 385–388 (2010).
   PubMed Web of Science ®Google Scholar
• Spina E , De Leon J. Metabolic drug interactions with newer antipsychotics a comparative review. Basic Clin. Pharmacol. Toxicol.100(1) , 4–22 (2007).
   PubMed Web of Science ®Google Scholar
• Titier K , CanalM, DéridetE et al. Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practice. Toxicol. Appl. Pharmacol. 199(1) , 52–60 (2004).
   PubMed Web of Science ®Google Scholar
• Wong SL , MenacherryS, MulfordD, SchmitzPJ, LockeC, GrannemanGR. Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function. Eur. J. Clin. Pharmacol.52(3) , 223–227 (1997).
   PubMed Web of Science ®Google Scholar
• Atmaca M , YavuzkirM, MermiO, TopuzM, KanmazE, TezcanE. Effect of sertindole on QTc interval in patients with schizophrenia. Neurosci. Lett.442(1) , 1–3 (2008).
   PubMed Web of Science ®Google Scholar
• Thomsen MB , VoldersPG, StenglM et al. Electrophysiological safety of sertindole in dogs with normal and remodeled hearts. J. Pharmacol. Exp. Ther. 307(2) , 776–784 (2003).
   PubMed Web of Science ®Google Scholar
• Rampe D , MurawskyMK, GrauJ, LewisEW. The antipsychotic agent sertindole was a high affinity antagonist of the human cardiac potassium channel HERG. J. Pharmacol. Exp. Ther.286(2) , 788–793 (1998).
   PubMed Web of Science ®Google Scholar
• Kang J , ChenXL, RampeD. The antipsychotic drugs sertindole and pimozide block erg3, a human brain K+ channel. Biochem. Biophys. Res. Commun.286(3) , 499–504 (2001).
   PubMed Web of Science ®Google Scholar
• Hartigan-Go K , BatemanDN, DalyAK, ThomasSH. Stereoselective cardiotoxic effects of terodiline. Clin. Pharmacol. Ther.60(1) , 89–98 (1996).
   PubMed Web of Science ®Google Scholar
• Ogura T , JonesS, ShubaLM, McCulloughJR, McDonaldTF. Block and modified gating of cardiac calcium channel currents by terodiline. Br. J. Pharmacol.127(8) , 1837–1845 (1999).
   PubMed Web of Science ®Google Scholar
• Ford GA , WoodSM, DalyAK. CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system. Br. J. Clin. Pharmacol.50(1) , 77–80 (2000).
   PubMed Web of Science ®Google Scholar
• Martin RL , SuZ, LimberisJT et al. In vitro preclinical cardiac assessment of tolterodine and terodiline multiple factors predict the clinical experience. J. Cardiovasc. Pharmacol.48(5) , 199–206 (2006).
   PubMed Web of Science ®Google Scholar
• Thomas SH , HighamPD, Hartigan-GoK et al. Concentration dependent cardiotoxicity of terodiline in patients treated for urinary incontinence. Br. Heart J. 74(1) , 53–56 (1995).
   PubMedGoogle Scholar
• Yang CW , HungSI, JuoCG et al. HLA-B*1502-bound peptides: implications for the pathogenesis of carbamazepine-induced Stevens–Johnson syndrome. J. Allergy Clin. Immunol.120(4) , 870–877 (2007).
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services FDA. Guidelines for industry: pharmacogenomic data submission. Biotechnology Law Report23(1) , 68–86 (2003).
   Google Scholar

Websites

• US FDA. Janssen Pharmaceutica stops marketing cisapride in the USA. FDA Talk Paper, FDA, Rockville, MD, USA (2000). www.fda.gov/ohrms/dockets/ac/00/backgrd/3634b1a_tab4a.htm
   Google Scholar
• Department of Health and Ageing. Consumer level recall of arthritis drug (2004). www.tga.gov.au/media/2004/040930_vioxx.htm
   Google Scholar